Techno Trends
TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.
Armata Pharmaceuticals Introduces Breakthrough AP-SA02 Therapy for Treating S. aureus Bacteremia
Armata Pharmaceuticals has introduced AP-SA02 for the adjunct treatment of complicated Staphylococcus aureus (S. aureus) bacteremia caused by methicillin-sensitive S. aureus (MSSA) or methicillin-resistant S. aureus (MRSA).
Revolution Medicines Introduces Breakthrough RASONQUE Therapy for Treating Metastatic Pancreatic Cancer
Revolution Medicines has introduced RASONQUE (daraxonrasib) in combination with chemotherapy for the treatment of metastatic pancreatic adenocarcinoma (PDAC), a common form of pancreatic cancer that can spread to other parts of the body.
UCB Introduces Breakthrough CIMZIA Therapy for Treating Antiphospholipid Syndrome
UCB has introduced CIMZIA (certolizumab pegol) for the prevention of placenta-mediated adverse pregnancy outcomes in pregnant women with antiphospholipid syndrome (APS), a rare autoimmune disorder
Biogen Introduces Breakthrough Salanersen Therapy for Treating Spinal Muscular Atrophy
Biogen has introduced salanersen for the treatment of spinal muscular atrophy (SMA), a rare genetic neuromuscular disorder that causes progressive muscle weakness and loss of motor function.
Lilly Introduces Breakthrough Olomorasib Therapy for Treating KRAS G12C-Mutant Advanced Pancreatic Cancer
Eli Lilly and Company has introduced olomorasib as a monotherapy for adults with previously treated advanced pancreatic cancer carrying a KRAS G12C mutation.
Praxis Introduces Breakthrough Elsunersen Therapy for Treating SCN2A Developmental and Epileptic Encephalopathy
Praxis Precision Medicines has introduced elsunersen (PRAX-222) for the treatment of seizures associated with SCN2A developmental and epileptic encephalopathy (SCN2A-DEE) caused by gain-of-function variants in the SCN2A gene.
MannKind Introduces First-and-Only Afrezza® Therapy for Treating Diabetes in Children and Adolescents
MannKind has introduced Afrezza® for the treatment of diabetes in children and adolescents aged six years and older requiring mealtime insulin therapy.
Regeneron Unveils 'First-and-Only' Otarmeni™ (lunsotogene parvec-cwha) for the Treatment of Genetic Hearing Loss
Regeneron Pharmaceuticals has introduced Otarmeni™ (lunsotogene parvec-cwha), the first and only treatment for OTOF-related genetic hearing loss in pediatric and adult patients with severe-to-profound sensorineural hearing loss.
VERTANICAL Introduces Breakthrough VER-01 Therapy for Treating Chronic Low Back Pain
VERTANICAL has introduced VER-01 for the treatment of chronic low back pain, a condition associated with persistent pain and functional impairment.
Wenda Pharma Introduces Breakthrough NHWD-870 Therapy for Treating NUT Carcinoma
Wenda Pharma has introduced NHWD-870 HCl for the treatment of advanced NUT carcinoma, a rare and highly aggressive cancer with limited treatment options and poor survival outcomes.
